Newer depression screeners successfully measure symptoms and follow progress of treatment

depressed
Credit: CC0 Public Domain

Depression is the second most disabling condition in the world, after pain, so screening and diagnosis are crucial to improving outcomes for patients, especially in light of the COVID-19 pandemic. Research from Regenstrief Institute and Indiana University School of Medicine shows that the Patient Reported Outcomes Measurement Information Systems (PROMIS) scale for depression developed by the National Institutes of Health accurately measures depression symptoms and severity.

"Depression is treatable, that's why is strongly recommended," said study lead author Kurt Kroenke, M.D., Regenstrief research scientist and IU School of Medicine professor of medicine. "Measurement-based care is important to track a patient's progress in order to make adjustments to care when needed. This study found that the PROMIS scales are an accurate measure of to aid in diagnosis and treatment."

The research team analyzed data from three randomized clinical trials involving about 650 patients. It compared the results of the PROMIS scale, which is a survey where patients report their symptoms, to the results of a structured psychiatric interview. They also compared the diagnostic performance of the PROMIS scale and Patient Health Questionnaire nine-item depression (PHQ-9), which has been validated and widely adopted around the world, to benchmark the PROMIS measures. The PHQ-9 was developed by Dr. Kroenke.

Data analysis showed that PROMIS and PHQ-9 depression scales have similar accuracy when diagnosing depression.

Credit: Regenstrief Institute

"PROMIS scales are already commonly in use, and both PROMIS and PHQ scales are accessible and free in the public domain. This research supports both as viable options," said Dr. Kroenke.

"The pandemic has taken a substantial toll on mental health, and there will likely be a lingering effect. Screening has become all the more important because we must be able to diagnose and treat patients who are suffering. Monitoring depression is no different than monitoring blood pressure, so these scales are important tools that are proven to work."

The paper, "Diagnostic operating characteristics of PROMIS scales in screening for depression," was published in the August 2021 print issue of the Journal of Psychosomatic Research.


Explore further

New score measures health-related quality of life in patients with kidney failure

More information: Kurt Kroenke et al, Diagnostic operating characteristics of PROMIS scales in screening for depression, Journal of Psychosomatic Research (2021). DOI: 10.1016/j.jpsychores.2021.110532
Citation: Newer depression screeners successfully measure symptoms and follow progress of treatment (2021, October 20) retrieved 8 December 2021 from https://medicalxpress.com/news/2021-10-depression-screeners-successfully-symptoms-treatment.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
12 shares

Feedback to editors